MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Dynamics of circulating VEGF-A predict benefit from anti-angiogenic cediranib in metastatic or recurrent cervical cancer patients

C Zhou, S Taylor, J Tugwood, K Simpson, G C Jayson, P Symonds, J Paul, S Davidson, K Carty, E McCartney, D Rai, C Dive, C West
British Journal of Clinical Pharmacology 2019 April 13
30980733

BACKGROUND AND PURPOSE: There is a need for predictive and surrogate response biomarkers to support treatment with anti-angiogenic VEGF inhibitors. We aimed to identify a minimally-invasive biomarker predicting benefit from cediranib pre-treatment or early during treatment in patients with recurrent or metastatic cervical cancer.

EXPERIMENTAL APPROACH: Blood samples were collected before treatment, during treatment and upon disease progression where appropriate from patients enrolled in CIRCCa, a randomised phase II trial of carboplatin and paclitaxel with or without cediranib. Plasma concentrations of VEGF-A, VEGF-R2, Ang1 and Tie2 were measured using multiplex ELISA. Pre-treatment and temporal changes of the biomarkers were investigated using proportional hazard regression and unsupervised clustering analysis.

KEY RESULTS: Samples (n=556) from 52 patients were analysed. VEGF-R2 (p=0.0006) and Tie2 (p=0.04) were down-regulated following cediranib, while VEGF-A (p=0.0025) was up-regulated. High ECOG performance status (p=0.02, HR=2.15, 95%CI 1.13-4.09) and low pre-treatment Tie2 concentrations (p=0.003, HR= 0.57, 95%CI 0.39-0.83) were independent prognostic factors associated with reduced progression-free survival. Two patterns of changes in VEGF-A following cediranib were identified. Patients with elevated VEGA-A in the first 3 treatment cycles, regardless of magnitude, had reduced progression-free survival in the placebo arm but improved survival with the addition of cediranib (p=0.019, HR= 0.13, 95% CI 0.02-0.71).

CONCLUSIONS AND IMPLICATIONS: Patterns of early elevation in plasma VEGF-A should be studied further as a potential biomarker to predict treatment benefit from cediranib.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30980733
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"